SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
From the Blogosphere
Sigma Designs Rallies; To Join S&P Small Cap 600 Index
Unusual 11 Mid-Day Movers 7/14: HITK, NOVN, NSU, IMMU Higher; SBGI, CPF, HNT, COBZ Lower
Hi Tech Pharmacal Co. Inc. (Nasdaq: HITK) <font>35.5% HIGHER;</font> reports Q4 EPS of $0.45, versus the consensus of $0.20 (one analyst) and $0.02 last year. Revenues rose 83% to $38.3 million versus the consensus of $29.2 million.Sinclair Broadcast Group (Nasdaq: SBGI) <font>31.5% LOWER;</font> continuing lower today following a 21% slide yesterday. Late Friday, Sinclair said in an SEC filing that it may be forced to voluntarily file for Chapter 11 Bankruptcy.Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) <font>22.1% HIGHER;</font> and Hisamitsu Pharmaceutical Co., Inc. have entered into a de...
|
Notable Mergers and Acquisitions of the Day 7/14: NOVN, MON, CNB/GHC
|
<> <>Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) and Hisamitsu Pharmaceutical Co., Inc. have entered into a definitive merger agreement pursuant to which Hisamitsu has proposed to acquire Noven for total cash consideration of approximately $428 million, or $16.50 per share, in an all-cash tender offer for 100% of the outstanding shares of Noven. The offer price represents a 22% premium to the closing price of Noven's common stock on July 13, 2009, and a 43% premium to Noven's average closing price for the preceding 90 days.The acquisition is expected to be effectuated through a cash tender offer...
|
Morning Movers 7/14: NOVN, CIT, CPST, CNB, BBI Higher; HNT, COBZ, CPF, TTWO, IBAS Lower
Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) <font>22.4% HIGHER;</font> and Hisamitsu Pharmaceutical Co., Inc. have entered into a definitive merger agreement pursuant to which Hisamitsu has proposed to acquire Noven for total cash consideration of approximately $428 million, or $16.50 per share, in an all-cash tender offer for 100% of the outstanding shares of Noven. Here is the full report.Health Net, Inc. (NYSE: HNT) <font>22.2% LOWER;</font> Health Net Federal Services, LLC, the government operations division of Health Net, released the following statement today in response to the Departm...
|
Is BioSante Next in the Biotech Buyout Binge?
|
|
|
<>
Earlier this week BioSante Pharma (BPAX) reported 3Q08 results which included a net loss of $6.6M or ($0.24) per share and a loss of $16.3M or ($0.60) per share for the first nine months of the year. The primary focus at the company is the development of LibiGel, which is currently being evaluated for both effectiveness and safety in three Phase 3 clinical trials for the treatment of female sexual dysfunction [FSD]. The Company ended 3Q08 with $17.5M in cash, compared to $22.8M at the end of 2Q08.
As illustrated on the accompanying all-data stock price chart for BPAX, the stock is now tradin...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on NOVN |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Noven Pharmaceuticals Inc
- Answers.com
